Trial Profile
An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs ABNCoV2 cVLP based COVID 2019 vaccine AdaptVac (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 25 Nov 2023 Status changed from active, no longer recruiting to completed.
- 21 Oct 2023 This trial has been discontinued according European Clinical Trials Database record.
- 16 Jun 2023 According to a Bavarian Nordic media release, company announced results of a 12-month follow-up analysis from a subset of subjects enrolled in this clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate